DNLI
Price
$13.67
Change
-$0.64 (-4.47%)
Updated
Jul 25 closing price
Capitalization
1.99B
4 days until earnings call
MEIP
Price
$6.74
Change
+$0.14 (+2.12%)
Updated
Jul 25 closing price
Capitalization
44.91M
Interact to see
Advertisement

DNLI vs MEIP

Header iconDNLI vs MEIP Comparison
Open Charts DNLI vs MEIPBanner chart's image
Denali Therapeutics
Price$13.67
Change-$0.64 (-4.47%)
Volume$1.18M
Capitalization1.99B
MEI Pharma
Price$6.74
Change+$0.14 (+2.12%)
Volume$590.33K
Capitalization44.91M
DNLI vs MEIP Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. MEIP commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and MEIP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (DNLI: $13.67 vs. MEIP: $6.74)
Brand notoriety: DNLI and MEIP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. MEIP: 46%
Market capitalization -- DNLI: $1.99B vs. MEIP: $44.91M
DNLI [@Biotechnology] is valued at $1.99B. MEIP’s [@Biotechnology] market capitalization is $44.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileMEIP’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • MEIP’s FA Score: 0 green, 5 red.
According to our system of comparison, MEIP is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while MEIP’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • MEIP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MEIP is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -2.36% price change this week, while MEIP (@Biotechnology) price change was +13.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.99B) has a higher market cap than MEIP($44.9M). MEIP YTD gains are higher at: 173.984 vs. DNLI (-32.924). MEIP has higher annual earnings (EBITDA): -22.17M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. MEIP (20.5M). MEIP has less debt than DNLI: MEIP (11.7M) vs DNLI (48.6M). DNLI (0) and MEIP (0) have equivalent revenues.
DNLIMEIPDNLI / MEIP
Capitalization1.99B44.9M4,423%
EBITDA-505.16M-22.17M2,279%
Gain YTD-32.924173.984-19%
P/E RatioN/A1.09-
Revenue00-
Total Cash818M20.5M3,990%
Total Debt48.6M11.7M415%
FUNDAMENTALS RATINGS
DNLI vs MEIP: Fundamental Ratings
DNLI
MEIP
OUTLOOK RATING
1..100
6050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
8834
P/E GROWTH RATING
1..100
9842
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEIP's Valuation (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than DNLI’s over the last 12 months.

MEIP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that MEIP’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as MEIP (98) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to MEIP’s over the last 12 months.

MEIP's Price Growth Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (88) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than DNLI’s over the last 12 months.

MEIP's P/E Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (98) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIMEIP
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 20 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTOS5.960.15
+2.58%
Custom Truck One Source
ARM163.173.18
+1.99%
Arm Holdings plc
THO95.361.78
+1.90%
Thor Industries
ZUMZ14.83-0.32
-2.11%
Zumiez
OVID0.62-0.07
-10.75%
Ovid Therapeutics

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-4.47%
BEAM - DNLI
63%
Loosely correlated
+3.68%
NRIX - DNLI
62%
Loosely correlated
-0.09%
IDYA - DNLI
60%
Loosely correlated
-1.33%
RGNX - DNLI
58%
Loosely correlated
-1.86%
ARWR - DNLI
57%
Loosely correlated
-3.20%
More

MEIP and

Correlation & Price change

A.I.dvisor tells us that MEIP and SYBX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEIP and SYBX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
+2.12%
SYBX - MEIP
31%
Poorly correlated
-4.79%
TELO - MEIP
31%
Poorly correlated
-4.37%
INMB - MEIP
26%
Poorly correlated
-2.34%
NRIX - MEIP
26%
Poorly correlated
-0.09%
DNLI - MEIP
26%
Poorly correlated
-4.47%
More